# FEMASYS INC (FEMY) — capital_raise/atm_program [pending]
Source: SEC API (secapi.ai) · situation sit_aaf7bce35585868f0471 · retrieved 2026-08-14T01:48:16.854Z

## Overview
Femasys Inc. is a medical device company that develops surgical and medical instruments and apparatus.

On August 7, 2026, Femasys Inc. entered into a Securities Purchase Agreement with accredited investors for a private placement that closed on August 10, 2026. The company issued 5,013,559 shares of common stock at $3.20 per share, 4,361,440 pre-funded warrants at $3.1999 per warrant (exercisable at $0.0001 per share), and 18,749,998 accompanying warrants (9,374,999 common warrants exercisable at $2.95 per share and 9,374,999 milestone warrants also exercisable at $2.95 per share). The common warrants are exercisable immediately and expire three years after issuance. The milestone warrants become exercisable only upon achievement of both U.S. revenue of at least $1,500,000 in any fiscal quarter and a volume-weighted average price of common stock equal to or greater than 130% of the exercise price for at least 20 of 30 consecutive trading days, expiring on the earlier of three years after the registration statement effective date or 45 days after the company notifies holders that milestones are satisfied. The company expects to receive approximately $30.0 million in aggregate gross proceeds before offering expenses.

## Terms
- Counterparty: Accredited investors (including Nantahala Capital Management, LLC as lead investor) · Deal value: $30.0M · Consideration: mixed · Price/share: $3.2

## Key dates
- Announced 2026-08-11

## Timeline
- 2026-08-11 · 8-K (0001140361-26-032247): 8-K - FEMASYS INC — *Femasys Inc. is a medical device company that develops surgical and medical instruments and apparatus.* On August 7, 2026, Femasys Inc. entered into a Securities Purchase Agreement with accredited investors for a private placement that closed on August 10, 2026. The company issued 5,013,559 shares of common stock at $3.20 per share, 4,361,440 pre-funded warrants at $3.1999 per warrant (exercisable at $0.0001 per share), and 18,749,998 accompanying warrants (9,374,999 common warrants exercisable at $2.95 per share and 9,374,999 milestone warrants also exercisable at $2.95 per share). The common warrants are exercisable immediately and expire three years after issuance. The milestone warrants become exercisable only upon achievement of both U.S. revenue of at least $1,500,000 in any fiscal quarter and a volume-weighted average price of common stock equal to or greater than 130% of the exercise price for at least 20 of 30 consecutive trading days, expiring on the earlier of three years after the registration statement effective date or 45 days after the company notifies holders that milestones are satisfied. The company expects to receive approximately $30.0 million in aggregate gross proceeds before offering expenses.
  https://www.sec.gov/Archives/edgar/data/1339005/0001140361-26-032247.txt

## Citations
- 0001140361-26-032247 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126032247